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We investigated the predictors of the risk of developing a second primary cancer after breast cancer, this occurring in about 12% of
affected women. The analysis included 335191 females, registered in the National Cancer Institute’s Surveillance Epidemiology and
End Results (SEER) database, who had been diagnosed with breast cancer. Observed numbers of subsequent cancers in the SEER
database with a first breast cancer diagnosed from 1973 to 2000 were compared with the expected numbers based on age-adjusted
incidence rates to calculate standardised incidence ratios. Kaplan–Meier curves were conducted to determine the median time until
the second primary cancer diagnosis. Average number of years until diagnosis varied by site and by age as well as median years until
second cancer diagnosis. Most cancer risks decreased with age, but there was an increase in aging-related cancers such as lung cancer.
The median years of follow-up were well beyond the 5-year mark. Breast cancer survivors should be advised of their increased risk
for developing certain cancers in their lifetime.
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Approximately, 600000 women in the US are diagnosed with
cancer in a given year, and 31% of them will be diagnosed with
breast cancer. Breast cancer is the leading cancer for women, and
deaths associated with breast cancer are second behind lung cancer
and account for 15% of all cancer deaths (American Cancer
Society, 2004). Survival rates (5, 10, and 20-year) continue to
increase and many women will survive their breast cancer
diagnosis and treatment (Rosen et al, 1989; Jones and Raghavan,
1993; American Cancer Society, 2004).
Second primary tumours may develop in women previously
diagnosed with breast cancer. Yet, little is known about the risk of
multiple primary tumours among breast cancer survivors. The
purpose of this study was to examine whether women diagnosed
with breast cancer have an increased risk of developing a
subsequent cancer compared with women of equal age without
an initial breast cancer diagnosis. The current study reports the
most common second primary tumours following breast cancer,
the time to diagnosis for women with a second tumour and how
overall survival is affected for these women.
MATERIALS AND METHODS
Population
The study population was derived from the SEER Cancer Registry
database, which encompasses approximately 11% of the national
cancer burden (Fritz and Ries, 1998; SEER*Stat software, 2004). All
patients in this study were women in the SEER Cancer Registry
diagnosed with breast cancer between 1 January, 1973 and 31
December 2000. There were 335191 women diagnosed with breast
cancer (International Classification of Diseases for Oncology 2
(ICD-O-2) code C50) (Percy et al, 1990). Women were included if
the breast cancer was categorised as in situ or malignant and if the
morphology was either ductal, lobular, or medullary neoplasm
(ICD-O-2 codes 8500–8540). A total of 2330 women developed a
second cancer, but the information was not completely entered
into the SEER database. These women were used in the survival
analysis, because survival status information was provided, but
these 2330 women were excluded from the incidence ratio
analyses. Another 3177 women had missing follow-up time. These
women were excluded from the survival analysis, but if they
developed a second cancer simultaneously, they were then
included in the incidence analyses. A total of 332014 women were
used in the survival analysis and were followed up until they were
diagnosed with their second tumour, December 2000, or death
before December 2000 whichever came first.
Definition of second primary tumours
Multiple primary tumours are difficult to distinguish from
metastatic tumours. The current study uses the SEER definition
to define multiple primary tumours. The SEER definition takes
into account, when determining multiple primary tumours, the site
of the tumour, behaviour of the second tumour, histology, date of
diagnosis, and the laterality if it is a paired organ (Fritz and Ries,
1998). Using this definition, metastatic and recurrent tumours are
excluded from multiple primary tumour counts. There are
exceptions and factors such as histology, laterality, and the date
of diagnosis that can alter the decision of determining multiple
Received 15 February 2006; revised 3 April 2006; accepted 18 April
2006; published online 23 May 2006
*Correspondence: JS Raymond, Rollins School of Public Health, Emory
University, 4770 Buford Hwy., MS-F40, Atlanta, GA 30341, USA;
E-mail: JRaymond@cdc.gov
British Journal of Cancer (2006) 94, 1745–1750
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yprimary tumours with paired organs. The SEER definition of
multiple primary tumours for the breast comprises the following
criteria:
  A single tumour with one histologic type is regarded as a single
primary tumour; a single tumour disposed with multiple
histologic types is regarded as a single tumour.
  A new tumour that contains the same histology as a previous
cancer and is diagnosed within 2 months of the previous cancer
is regarded as a single primary unless determined to be a
recurrent or metastatic cancer.
  Simultaneous multiple tumours with the same histologic type
within the breast are regarded as a single tumour, and even
when different tumours have different behaviour codes.
  Simultaneous bilateral involvement of the breasts with only one
histology is regarded as a single primary tumour.
  Multiple tumours with the same histologic type appearing in the
breast and in a different site are regarded as multiple primary
tumours unless stated as metastatic tumours.
  Multiple tumours of different histologic types within the breast
are counted as multiple primary tumours regardless of time.
  Multiple tumours of different histologic types appearing in the
breast and in a different site are multiple primary tumours
regardless of time (Fritz and Ries, 1998; Howe et al, 2003).
Analysis of risk of second primary tumours
The primary variable considered as the exposure in the first part of
the analysis was the type of cancer the women developed after
breast cancer. These women were then stratified into 10-year age
groups for analysis. Age was determined by the age of each woman
at the date of diagnosis for breast cancer. Data were analysed using
STATA software (STATA Corporation, 2002). Risks are considered
significant when corresponding 95% confidence interval did not
include the null value. The risk was calculated for 14 second
primary tumours in addition to an overall risk for second primary
tumours in 10-year age periods. These were selected because there
were at least 100 cases to analyse or showed to be statistically
significant.
To control for potential confounding of the differences in age
distributions, age-adjusted incidence rates were used for compar-
ison. Age/period-specific cancer incidence rates from the SEER
database were applied to the cohort, to calculate the number of
subsequent tumours that would be expected for each site. This
number was compared with the observed number to obtain a
standardised incidence ratio (SIR) estimate and 95% confidence
intervals (CI) were calculated assuming a Poisson distribution.
Those sites that were statistically significant or showed an
association with breast cancer were listed.
The cohort includes women diagnosed at earlier ages who
survive cancer to the next 10-year age group. For example, women
diagnosed before age 30 are included in older age groups if they
did not have a second primary tumour diagnosis before age 30.
Subsequent data accumulate cohorts similarly.
Analysis of time to diagnosis for women with second
primary tumour
For the women who were diagnosed with a second primary
tumour, univariate analysis was performed using Kaplan–Meier
curves, to estimate the time function diagnosis. Curves were
calculated for all sites combined and for specific sites with at least
100 cases, and women were divided into decades of age at breast
cancer diagnosis, 20–29, 30–39, 40–49, 50–59, 60–69, and 70 and
older. Several exposure variables were explored in univariate
analyses. Variables of interest were grouped and coded accord-
ingly. These include multiple status, grade, AJCC stage or
summary staging, and race. All variables were significant in the
univariate analysis and included in the multivariate analysis.
Multivariate analysis was determined between groups assessed by
goodness of fit (GOF) methods (Kaplan and Meier, 1958; Lee, 1980;
Snedecor and Cochran, 1980).
RESULTS
Of those diagnosed with breast cancer during 1973–2000, 40068
women developed one additional cancer after breast cancer, 3796
women developed two cancers, 351 women developed three
cancers, 31 women developed four cancers, and 3 women
developed 5 cancers. Of these women, 0.76% were diagnosed by
age 29, 6.79% between 30 and 39, 19.72% between 40 and 49,
21.19% between 50 and 59, 22.34% between 60 and 69, and 29.20%
at or after age 70. Second cancers were subsequently reported for
11.7% of the patients who were diagnosed with breast cancer
before age 50, and 17% of patients diagnosed with breast cancer at
or after age 50. Among women with a second tumour diagnosed,
the mean time until the second cancer occurred was 6.2 years: 8
years for patients less than 50-years old and 5.7 years for women at
or greater than age 50. Among women with a single breast cancer
diagnosis, the average time from diagnosis of the breast cancer
until death was 6.71 years for women less than 50-years old, and
4.5 years for women at or greater than age 50. 60.28% of the
women were still alive at the end of follow-up.
The results of the standardised incidence ratio analysis are
found in Table 1. For women diagnosed with breast cancer by age
29, the overall second primary tumour risk is large (SIR¼17.3,
95% CI¼13.7, 21.6), as is the risk of developing a second breast
cancer (SIR¼478.5) or stomach cancer (SIR¼145.4). As age at
primary diagnosis increases, the overall SIR’s decrease until the
eldest age group. Cancer sites with the highest ratios for women
diagnosed with breast cancer before age 50 include bone, breast,
leukaemia, lung, and ovary. However, having a breast cancer
diagnosis was protective against cancer of the cervix for these age
groups. For women who did not develop breast cancer until at least
50 years old, the overall SIR for developing a second cancer by age
59 was 2.7, which is much lower than risks among some of the
earlier age groups. Again, the overall ratios decrease with age.
Cancer sites with the highest SIR’s were breast, colon/rectum,
corpus uteri, lung, ovary, skin, and thyroid. Among older women,
an initial breast cancer diagnosis was not protective against
cervical cancer. Overall, both excess risk and protective effects
decreased with age for most of the 14 cancers examined. For
example, the SIR for a second breast cancer was greatest for
women 20–29 years of age (478.53) and decreased dramatically
and consistently after age 30 (Table 1).
Table 2 presents the data comparing the SIR’s of a second breast
cancer diagnosis with a second non-breast cancer diagnosis within
10-year time intervals. For women diagnosed with breast cancer by
age 29, their risk of developing a second primary tumour other
than breast within 10 years of their initial diagnosis is large
(SIR¼8.9, 95% CI¼8.27, 9.60), but their risk for developing a
second breast cancer, within the same 10 years, is five and a half
times greater (SIR¼48.4, 95% CI¼46.5, 50.3). But after 20 years,
these same women actually showed a protective effect against both
cancer groups, breast and other, compared to the general
population (SIR¼0.2, 95% CI¼0.2, 0.3; SIR¼0.5, 95% CI¼0.4,
0.6). For women diagnosed with breast cancer at or after age 70,
their risk for developing either a second breast cancer or a second
primary cancer, other than breast within 10 years, is virtually the
same (SIR¼1.84, 95% CI¼1.8, 1.9; and SIR¼1.6, 95% CI¼1.5,
1.7). In general, most women had a more elevated risk of
developing a second breast cancer, than a second primary cancer
other than breast, but both risks were greater for these women
than the general population. The risk reduced with time and age
for all groups.
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until second primary cancer diagnosis, stratified on age at
diagnosis of the breast cancer and limited to the 12.3% of women
who were diagnosed with a second primary tumour. The median
years of follow-up until the second cancer is diagnosed ranged
from 2.3 years for women over 70 developing cervix uteri to 18.08
for women 30–39 developing a second breast cancer. The
difference in follow-up time for the age groups can be attributed
to (1) a longer at-risk period for women o50 years for developing
the second cancer and (2) the increased risk of developing some
cancers at an advanced age.
Figure 1 illustrates the median ages at the time of the second
cancer diagnosis for each of the 14 cancers. Cervix uteri cancer has
the youngest median age with 59 years, while colon/rectum cancer
has the oldest median age with 75 years.
Survival analysis was then constructed stratifying on the women
who only developed breast cancer and those women who were
diagnosed with breast cancer and a second primary cancer.
Survival curves were adjusted for race and grade. In the 20–29
year old category, grade was categorised as an ordinal variable.
Figure 2 illustrates survival analysis for women 20–29 years old
diagnosed with breast cancer in or after 1988, stratified on multiple
tumour status, controlling for race (P¼0.621) and grade
(P¼0.511). The figure shows women with multiple primary
cancers had poorer survival than women with only a breast cancer
diagnosis over time. Women in this young age group who had
metastatic breast cancer have a 15-year survival probability of only
23.23%.
In general, overall survival was poorer for women with multiple
primary tumours compared with women with no second tumours.
In addition to second tumours, grade of the breast cancer, race,
and extent of disease played a role in determining the survival for
each age group. A woman with a higher-grade breast tumour
followed by a second tumour had much poorer survival than a
woman with a low-grade breast tumour followed by a second
tumour. This is also true for the extent of disease. Time also acted
as a contributing factor to poorer survival.
Table 1 Standardized incidence ratios for a second primary cancer diagnosis by decade age at risk
20–29 30–39
a 40–49 50–59 60–69 70+ 50–59
b 60–69
b 70+
b
Percent
Age/Cancer N SIR N SIR N SIR N SIR N SIR N SIR N SIR N SIR N SIR Total %
All sites 78 17.3 1037 5.9 4547 2.37 2968 1.64 4720 2.67 10393 1.74 20506 1.33 44,249
Breast 65 478.5 857 21.8 3463 4.14 1507 2.19 387 1.45 3118 4.63 5268 2.83 8262 2.11 22,927 51.81
Other cancers 13 4.4 180 1.3 1461 1.3 526 0.9 71 0.8 1602 1.3 5125 1.3 12244 1.1 21,322 48.19
Bone 1 20.1 3 8.2 7 4.39 11 2.17 22 0.05
Brain 1 9.3 1 0.00
Cervix uteri 39 0.5 140 0.55 57 0.68 8 0.35 160 0.72 404 0.91
Colon/Rectum 82 0.77 11 0.54 214 1.42 869 1.18 3145 1.07 4,321 9.77
Connective tissue 6 5.9 49 2.4 105 1.79 160 0.36
Corpus uteri 189 1.17 49 0.67 207 1.31 679 1.34 1273 1.61 2,397 5.42
Leukaemia 3 27.4 69 2.2 72 1.81 64 1.64 259 1.45 467 1.06
Lung 17 6.7 127 1.31 228 1.24 303 1.69 978 1.25 1854 1.12 3,507 7.93
Ovary 2 16 27 5 153 1.9 141 1.77 147 1.89 338 1.47 531 1.11 1,339 3.03
Pancreas 3 6.8 112 4.25 488 0.88 603 1.36
Skin 15 104 1.63 32 1.48 107 1.71 264 1.76 559 1.58 1,049 2.37
Stomach 1 145.4 1 11 0.14 13 0.03
Thyroid 17 1.9 46 1.64 61 2.23 77 1.53 113 1.38 314 0.71
All numbers represents an elevated risk that is statistically significant by 95% confidence intervals.
aWomen diagnosed before age 30 are included if they did not have a primary
tumour diagnosis before age 30. Subsequent tables accumulate cohorts similarly.
bThe first diagnosis of breast cancer occurred at or after age 50.
Table 2 Standardized incidence ratios categorised by either a second breast cancer diagnosis or a second primary cancer other than breast cancer, by
time intervals after first diagnosis of breast cancer
Less than 10 years after initial breast cancer 10–19 years after initial breast cancer 20–29 years after initial breast cancer
Second primary
breast cancer
Second primary
non-breast cancer
Second primary
breast cancer
Second primary
non-breast cancer
Second primary -
breast cancer
Second primary -
non-breast cancer
Age in years SIR 95% CI SIR 95% CI SIR 95% CI SIR 95% CI SIR 95% CI SIR 95% CI
20–29 48.4 (46.5, 50.3) 8.90 (8.3, 9.6) 11.5 (10.6, 12.4) 1.46 (1.3, 1.2) 0.2 (0.2, 0.3) 0.5 (0.4, 0.6)
30–39 44.1 (42.3, 45.9) 2.79 (2.6, 3.0) 2.1 (1.9, 2.3) 1.35 (1.2, 1.5) 0.3 (0.2, 0.3) 0.3 (0.3, 0.4)
40–49 12.1 (11.6, 12.6) 4.08 (3.8, 4.3) 1.3 (1.2, 1.4) 0.88 (0.8, 1.0) 0.3 (0.2, 0.3) 0.0 (0.0, 0.05)
50–59 10.9 (10.6, 11.3) 4.75 (4.6, 5.0) 1.5 (1.4, 1.6) 0.99 (0.9, 1.1) 0.1 (0.1, 0.2) 0.2 (0.2, 0.2)
60–69 6.4 (6.2, 6.6) 2.99 (2.9, 3.1) 0.4 (0.3, 0.4) 0.50 (0.5, 0.5) 0.1 (0.1, 0.1) 0.1 (0.1, 0.2)
70+ 1.8 (1.8, 1.9) 1.60 (1.5, 1.7) 0.2 (0.2, 0.2) 0.30 (0.3, 0.3) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1)
Table 3 Point estimates for overall time until second primary cancer
diagnosis, stratified on age, and limited to the 12.3% of women who were
diagnosed with a second primary tumour
Age at diagnosis 75% 50% 25%
20–29 10.5 5.5 1.9
30–39 16.9 11.1 4.2
40–49 9.9 4.3 0.9
50–59 10.5 4.8 1.1
60–69 8.8 4.4 1.2
70+ 6.0 2.7 0.4
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Changes in both the breast cancer incidence and the mortality
rates have been documented in the past 25 years (Young et al,
2001). Evidence shows a fundamental increase in incidence, which
is partly attributed to the improved screening and diagnostic
techniques as well as to the changes in reproductive patterns, that
is, women waiting until later to have children. Mortality rates had
been relatively constant from 1973 to 1990. Since 1990, mortality
rates have decreased by 2.3% overall. This decrease was more
pronounced in women diagnosed with breast cancer before age 50
than with women aged 50 or older and have been attributed to the
improvement of the various cancer treatments (Ries et al, 2003).
Recent data have shown an overall survival rate for women
diagnosed with breast cancer at least 5 years before to be as high as
87% but drops to 77% for the 10-year mark and to 52% by the
20-year mark (Ries et al, 2003). Given the increase in incidence and
survival, it is important to assess health risks for breast cancer
survivors.
Using a standard method, population-based data were collected
from high-quality registries that covered approximately 11% of the
US population. The study provided a unique opportunity to study
a large number of women, over 335000, across several years
(1973–2000). This is the largest and most comprehensive study to
date of cancer among breast cancer survivors. An international
study (Chu et al, 1999) that examined the risk of a second primary
tumour following an initial breast cancer diagnosis, only assessed
risk for two age groups: o50 and X50 years old; this also used the
International Association for Research on Cancer definition of a
second primary cancer, which is not widely used in the US.
Another study examined women developing sarcoma after breast
cancer, using the Surveillance, Epidemiology, and End Results
(SEER) program data from 1973 to 1997 (Yap et al, 2002). The
major drawback in this study was that it included only patients
with invasive breast cancer.
This study found that 12.3% of breast cancer survivors were
diagnosed with second primary malignant tumours among breast
cancer survivors. Excess risks for 13 specific cancers were found,
with the highest excess risks for breast. Among women with a
second primary tumour, the time to second diagnosis varied by
type of tumour and age at diagnosis of the first tumour. The results
in this study are comparable to other findings regarding second
primary breast cancer (Berstein et al, 2003). As expected, the risk
of several cancers, including lung cancer, increased with age.
These results may help to inform patients and clinicians
regarding expected quality of life for breast cancer survivors
(Cimprich et al, 2002). A greater understanding of the patient’s
prognosis would assist both the patients and the clinician in
treatment options. For example, if a woman understands her risks
for developing a second primary cancer, she may choose to alter
her treatment to be more aggressive in hopes of minimizing her
risk. She may also need to be counselled regarding preventable risk
factors, such as weight gain, that have been associated with
premature mortality for women with a second breast cancer in
other studies (Bernstein et al, 2002).
In this study, breast cancer survivors had the greatest risk for
developing breast, bone, colon/rectal, connective tissue (sarcoma),
leukaemia, lung, ovarian, and thyroid cancer. There are several
possible explanations for these correlations, including genetic
mutations. Four possible genetic mutations have been identified
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Figure 1 Median age at cancer diagnosis for second primary tumours.
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Figure 2 Survival analysis for women 20–29 years old diagnosed with
breast cancer in or after 1988, stratified on multiple tumour status,
controlling for race or grade.
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develop multiple primary tumours. All four of these genetic
mutations include breast cancer and other cancers. BRCA1 and
BRCA2 are considered to be the breast cancer genes, but BRCA1 is
also associated with ovarian cancer (Szabo and King, 1997).
BRCA2 is associated with multiple primary tumours including
breast, colorectal, ovarian and other cancers. Ovarian cancer, like
breast cancer, is an oestrogen-driven cancer. Thus oestrogen is the
most obvious link between the two cancers. However, the risk of
ovarian cancer is also increased with the presence of the BRCA1
gene mutation (Szabo and King, 1997). Both BRCA1 and BRCA2
may bestow a heightened sensitivity to carcinogenic effects of
radiation (Ford et al, 1994; Turner et al, 1999). Recently studies
have shown a possible association between lung cancer and BRCA1
and BRCA2 mutation (Bergfeldt et al, 2000).
Multiple primary cancers, including acute adult leukaemia, have
been associated with a family history of breast cancer (Rauscher
et al, 2002). P53, known as Li–Fraumeni Syndrome, is associated
with the development of cancer at a young age and is associated
with breast cancer, sarcoma, brain cancer, and leukaemia (Lee,
1980). Women with P53 mutation have a lifetime probability of
almost 100% for developing at least one of these cancers. Lastly the
genetic mutation PTEN or Cowden Disease increases the risk for
both breast and thyroid cancer.
Breast cancer survivors appeared to have protection from
developing cervical cancer. Low socioeconomic status is a risk
factor for cervical cancer while high socioeconomic status is a risk
factor for breast cancer. However, the causal relationship under-
lying these associations is not well understood.
Breast cancer was associated with increased risk of connective
tissue cancer for several of the age groups. Two possible
explanations are (1) many women with breast cancer undergo
radiation, which increases a woman’s risk for connective tissue
cancer in the surrounding areas and (2) some genetic mutations,
including Li–Fraumeni Syndrome are linked with both breast
cancer and connective tissue cancer (Malkin et al, 1990; Rubino
et al, 2003).
Radiation may also increase the risk of lung cancer (Matesich
and Shapiro, 2003; Roychoudhuri et al, 2004). During the 1950s,
most of the upper body was exposed to radiation as the treatment
for breast cancer. This exposure included the thyroid, lungs,
breasts, and chest wall. This excess risk should therefore decrease
as the cohort exposed to high doses of radiation doses ages. As well
as radiation, chemotherapy as a treatment option for breast cancer
may be a risk factor for developing leukaemia as a second primary
cancer.
Among women who developed a second tumour, the time to
cancer varied by age. Risk for cancer generally increases with age.
This is most evident for the ‘older age’ cancers such as colorectal,
in which median years to second diagnosis decreased from 18 for
the 20–29 year group to less than four for the 70þ year group.
Other age-dependent cancers were ovarian (median years ranging
from 11 to less than 4) and pancreas (median years ranging from
15 to about 4). In the past, clinicians used as a general rule that if a
woman is cancer free for 5 years after the initial diagnosis, then she
is cured of cancer. This analysis shows that a sizeable proportion
of women who developed a second tumour were cancer-free 5
years after their initial diagnosis. With the exception of the oldest
group, the median time to diagnosis exceeded 5 years for the
women who had a second tumour. For women who were diagnosed
with breast cancer between the ages of 30 and 39, the median
number of years until they were diagnosed with any second
tumour was 11.42 years. This long lapse for the 30–39 year old age
group is primarily due to the fact that the median number of years
until a second breast cancer diagnosis was 18.08 years. It appears
that the women in this age group are treated very aggressively and
tend to have mastectomies performed on them. The only second
cancer where the median number of years was less than 5 was
cancer of the cervix uteri, but this estimate is probably unrealistic
because of the small number of women who developed cancer of
the cervix uteri after breast cancer. On the other hand, connective
tissue cancer had a median number of years until diagnosis of over
10 years, except for the 70þ age group.
This study has several limitations. Although population-based
cancer registries provide the opportunity to study these rare
events, the registries lack some important variables such as
smoking status, specific doses of treatment, and genetic make-up.
Also, quality of data used for classifying multiple primary
tumours is not under the control of the registries and may vary
across site and over time. Even studies that used data sets known
to be accurate found errors that affected the interpretation
(Bergfeldt et al, 2000). Finally, missing and incomplete data may
introduce measurement error. In this study, 5.7% of women
known to have been diagnosed with a second tumour were
excluded from the incidence risk analysis because of unknown
diagnosis. If the distribution of the tumour sites in these women is
substantially different from the distribution of known tumour
sites, results for some of the more rare tumours may be biased.
However, the number of unknown tumours is unlikely to have
affected the risks from the more frequent tumours. Whatever bias,
if present, is likely to be small, as there are striking similarities
in results from published studies of selected second tumours
(Yap et al, 2002).
In conclusion, it is clear that some women who survive breast
cancer are at increased risk of additional cancers. Excess risks
attenuate with increasing age at first diagnosis and with in-
creasing years since first diagnosis. Excess risk also varies by
cancer type, consistent with existing causal hypotheses regarding
genetics mutations and risk of aggressive radiation therapy.
More research should focus on isolating the factors that may
predispose a breast cancer survivor to the development of
subsequent cancers.
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